Format
Sort by

Send to:

Choose Destination

Results: 2

1.

Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET.

Janjigian YY, Viola-Villegas N, Holland JP, Divilov V, Carlin SD, Gomes-DaGama EM, Chiosis G, Carbonetti G, de Stanchina E, Lewis JS.

J Nucl Med. 2013 Jun;54(6):936-43. doi: 10.2967/jnumed.112.110239. Epub 2013 Apr 11.

2.

Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer.

Dijkers EC, Oude Munnink TH, Kosterink JG, Brouwers AH, Jager PL, de Jong JR, van Dongen GA, Schröder CP, Lub-de Hooge MN, de Vries EG.

Clin Pharmacol Ther. 2010 May;87(5):586-92. doi: 10.1038/clpt.2010.12. Epub 2010 Mar 31.

PMID:
20357763

Supplemental Content

Loading ...
Write to the Help Desk